
Sign up to save your podcasts
Or


Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.
Timestamps
1:16 - Panel introductions
References
Fidaxomicin Cost-effectiveness
Bezlotoxumab
Bezlotoxumab Cost-effectiveness
Primary prophylaxis
Secondary prophylaxis
By Society of Infectious Diseases Pharmacists4.9
166166 ratings
Dr. Kevin Garey (@GareyKgarey), Dr. Kelly Reveles (@KellyReveles), Dr. Mandelin Cooper, and host Dr. Rachel Britt (@RachelBPharmD) discuss proposed updates of the IDSA-SHEA C. difficile guidelines, including: fidaxomicin over oral vancomycin as first-line therapy, the roles and logistical hurdles of fecal microbiota transplant, bezlotoxumab, and the pros and cons of prophylaxis.
Timestamps
1:16 - Panel introductions
References
Fidaxomicin Cost-effectiveness
Bezlotoxumab
Bezlotoxumab Cost-effectiveness
Primary prophylaxis
Secondary prophylaxis

1,867 Listeners

2,055 Listeners

498 Listeners

129 Listeners

3,357 Listeners

1,144 Listeners

369 Listeners

248 Listeners

249 Listeners

374 Listeners

185 Listeners

32 Listeners

83 Listeners

269 Listeners

3 Listeners